ISSN 0004-2749 printed version
Scope and policy
ABO-ARQUIVOS BRASILEIROS DE OFTALMOLOGIA (ABO, ISSN 0004-2749 - printed version and ISSN 1678-2925 - online version) is the official bimonthly publication of the Brazilian Council of Ophthalmology (Conselho Brasileiro de Oftalmologia). The purpose of the journal is to publish scientific studies in Ophthalmology, Visual Sciences, and Public Health, encouraging research, as well as qualification and updating of the professionals involved in this field.
Original manuscripts are accepted in Portuguese, English, or Spanish. Manuscripts are grouped into one of the following categories based on the methodology used:
Laboratory Experimental Studies
Types of Manuscripts
Manuscripts submitted to ABO should fit into one of the following categories according to their format. The maximum number of words, figures, tables and, references for each type of manuscript are in parentheses at the end of the description for each category. The word count of the manuscript includes the text from the beginning of the introduction up to the end of the discussion; therefore, the following items are not included: title page, abstract, references, acknowledgments, tables and figures, including legends.
Editorials are contributed by invitation and should be related to topics of current interest, preferentially related to articles published in the same issue of ABO (title, maximum of 1,000 words, 2 figures or tables, and 10 references).
Original articles present complete experiments with results that have never been published before (title, structured abstract, maximum of 3,000 words, 7 figures or tables, and 30 references). The evaluation of the manuscripts will be based on the following priorities:
* Manuscripts containing speculative conclusions, unsubstantiated by the results or based on a study with inappropriate methodology will not be accepted.
Case Reports and Case Series
Case reports or case series will be considered for publication when describing rare and original findings that have not been internationally confirmed, or when presenting clinical or surgical responses that can contribute to elucidate the pathophysiology of a disease (title, unstructured abstract, maximum of 1,000 words, 4 figures or tables, and 10 references).
Letters to the Editor
Letters to the editor are considered for publication if they contain comments related to manuscripts previously published in ABO or, exceptionally, the results of original studies with insufficient content to be submitted as Original Article. These letters should present new information or new interpretation of existing information. When the content of the letter refers to an article previously published in ABO, such article should be mentioned in the first paragraph of the letter and included in its reference list. In these cases, the letters will be linked to the article, and the authors of the article will have their right of reply guaranteed in the same issue. Congratulation letters will not be published (title, maximum of 700 words, 2 figures or tables, and 5 references).
Review articles follow the editorial line and are contributed only by invitation from the editor. Suggestions of topics for review articles can be sent directly to the editor, but manuscripts cannot be sent without an invitation (title, unstructured abstract, maximum of 4,000 words, 8 figures or tables, and 100 references).
Manuscripts will only be considered for publication if they meet all the journal's requirements. The editorial office will inform the authors if their manuscript fails to meet such requirements. Upon notification, the corresponding author will have 30 days to make the necessary changes in the manuscript. If the deadline is not met, the manuscript will be excluded from the editorial process.
The manuscripts submitted to ABO are initially evaluated by the editors to check for content compliance with the editorial line of the journal. After this assessment, all manuscripts are sent for peer review. The anonymity of reviewers is preserved throughout the whole process. However, the authors of manuscripts do not remain anonymous.
After the initial editorial evaluation, the reviewers' comments can be sent to the authors to guide the changes to be implemented in the text. After implementing the changes suggested by the reviewers, the revised manuscript should be resubmitted along with a letter (which is sent as a supplementary document) with specific indications of all changes made to the manuscript or the reasons why the suggested changes were not made. The manuscripts that are resubmitted without a letter will be withheld until the letter is received by the editorial office. The deadline to submit the new version of the manuscript is 30 days after the authors are informed of the need to make changes in their manuscript. The manuscript will be excluded from the process if the authors fail to meet this deadline. The publication will be based on the final approval of the editors.
The manuscripts submitted to ABO should not be simultaneously considered for publication by other journals. In addition, total or partial publication or translation for publication in another language of the manuscripts submitted to ABO should not be considered without the permission of the editors of ABO.
The criteria for authorship of manuscripts in medical journals are well established. Individuals who have contributed in a concrete way during the following three phases of manuscript preparation should be considered authors:
The authors of manuscripts submitted to ABO should make sure that all authors meet the criteria mentioned above and that all persons who meet these criteria are listed. Individuals who hold headship positions cannot be considered authors of manuscripts based only on their positions. ABO does not accept the participation of honorary authors.
The corresponding author should complete and submit the Author Contribution Statement as a supplementary document.
Manuscripts should only be submitted online using the appropriate interface of ABO. The following guidelines were based on the format suggested by the International Committee of Medical Journal Editors (ICMJE) and published in the document: Uniform Requirements for Manuscripts Submitted to Biomedical Journals.
Only the manuscripts complying with these guidelines will be considered for analysis.
The text should be sent as a digital file. Only the following formats are accepted: .doc or .rtf. The text should be typed double-spaced, in 12 point font. The pages should be numbered in Arabic numerals, starting each section on a new page.
The sections should be presented according to the following sequence: Title page; Abstract and Keywords; Introduction; Methods; Results; Discussion; Acknowledgements (if any); References; Tables (optional) and Figures (optional) including legends.
Approval of the Institutional Review Board (IRB). All retrospective,
cross-sectional, or prospective studies involving primary data collection
or clinical and surgical reports should include the project number and
name of the institution that provided the approval of the IRB on the title
page. Studies involving humans should be compliant with the Declaration
of Helsinki, whereas studies involving animals should be in accordance
with the principles suggested by the Association for Research in Vision
and Ophthalmology (ARVO).
Statement of Conflicts of Interest. The title page should contain the statement of conflicts of interest of all authors (even if there is no conflict of interest). For more information about potential conflicts of interest, refer to: Chamon W, Melo LA Jr, Paranhos A Jr. Declaração de conflito de interesse em apresentações e publicações científicas. Arq Bras Oftalmol. 2010;73(2):107-9 or World Association of Medical Editors: Conflict of interest in peer-reviewed medical journals.
All authors should send the Form for Disclosure of Potential Conflicts of Interest as supplementary documents.
Clinical Trials. All Clinical Trials shall include on the title page the registration number in an international registry that allows free access to trial information (examples: U.S. National Institutes of Health, Australian and New Zealand Clinical Trials Registry, International Standard Randomised Controlled Trial Number - ISRCTN, University Hospital Medical Information Network Clinical Trials Registry - UMIN CTR,Nederlands Trial Register).
Before submitting their manuscript, authors should make sure that all the following items are available:
List of Websites
[Home] [About the journal] [Editorial board] [Subscriptions]
All the content of the journal, except where otherwise noted, is licensed under a Creative Commons License
Rua Casa do Ator, 1117 / Cj. 21
04546-004 - São Paulo, SP
Fone: + 55 11 3266-4000/ Fax: + 55 11 3171-0953